SCHEMBL1720540

SCHEMBL1720540

COc1ccc2c(C3CCN(C)CC3)c[nH]c(=O)c2c1

nearest known ligand 0.71

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 8/20 0.50
HTR1A P08908 7/20 0.50
APP P05067 2/20 0.49
DRD2 P14416 4/20 0.48
HTR7 P34969 4/20 0.48
HTR6 P50406 4/20 0.48
HTR2A P28223 3/20 0.48
HTR1D P28221 2/20 0.47
HTR1B P28222 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
THPO P40225 1/20 0.47
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47
HTR1F P30939 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1719925 0.83 HTR1D (0.50) HTR1AAPPHTR1DHTR1BCYP1A2
SCHEMBL7710792 0.83 HTR1D (0.67) SLC6A4HTR1AAPPDRD2HTR7
SCHEMBL1719682 0.82 HTR1D (0.49) HTR1AAPPHTR6HTR1DHTR1B
SCHEMBL1719808 0.82 SLC6A4 (0.53) SLC6A4HTR1AAPPDRD2HTR7
Hydrochloric Acid SCHEMBL1720644 0.81 SLC6A4 (0.52) SLC6A4HTR1AAPPDRD2HTR7
SCHEMBL1720950 0.80 HTR1D (0.47) HTR1AAPPHTR1DHTR1BCYP1A2
SCHEMBL1720025 0.80 KDM4E (0.57) HTR1AAPPHTR6HTR2AHTR1D
SCHEMBL1720798 0.79 APP (0.47) HTR1AAPPHTR1DHTR1BCYP1A2
SCHEMBL1720375 0.77 SLC6A4 (0.53) SLC6A4HTR1AAPPDRD2HTR7
SCHEMBL25072243 0.76 MTNR1A (0.65) SLC6A4HTR1AAPPDRD2HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP claimed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US claimed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US claimed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP claimed
EP-1566380-B1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2012-01-11 EP disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-7501412-B2 Isoquinoline compounds and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2009-03-10 US disclosed
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2006-05-04 US disclosed
EP-1566380-A1 ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2005-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094743-A1 Isoquinoline compounds and medicinal use thereof PARP1, NQO1, PARP3 SLC6A4 1822/4885HTR1A 2300/4885APP 1609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.